TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

Study NCT05473910: link below

https://clinicaltrials.gov/ct2/show/NCT05473910?term=TScan&draw=2&rank=

excerpt:

"The primary endpoints are: (1) incidence of dose-limiting toxicities (DLTs), and (2) incidence of adverse events (AEs) and serious AEs (SAEs) of TSC-100 and TSC-101 combined with the standard of care (SOC) compared with the SOC alone at 2 years of follow-up. The study will also investigate the efficacy of TSC-100 and TSC-101 combined with the SOC compared with that of the SOC alone to treat the study population and assess the immunogenicity of TSC-100 and TSC-101."

Theoretically, successful involvement of TSC-100 and TSC-101 in SOC would truly be a breakthrough. Monumental potential, if results warrant inclusion in SOC.